CESAR GARCIA: Open Payments
NPI 1912534819 · MCALLEN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$801 in 37 payments from 9 companies in 2025. Trend: 2023 $5,291 · 2024 $1,224 · 2025 $801
Food & beverage: $640Education: $161
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 18 | $360 |
| AstraZeneca Pharmaceuticals LP | 5 | $143 |
| GlaxoSmithKline, LLC. | 3 | $65 |
| Amgen Inc. | 3 | $52 |
| Dexcom, Inc. | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Abbott Laboratories | 2 | $39 |
| Boston Scientific Corporation | 1 | $27 |
| Optinose US, Inc. | 1 | $23 |
Products named: Ozempic, AIRSUPRA, Wegovy, AREXVY, Dexcom G6 Transmitter, REXULTI, FARXIGA, OTEZLA.
Industry payments across TX — which companies pay providers there.
